IceCure Medical announces new preliminary data on ProSense

IceCure Medical announced new data from a preliminary, independent breast cancer study conducted by Principal Investigator and ProSense user, Dr. Federica. di Naro, of Azienda Ospedaliero-Universitaria Careggi, Diagnostic Senology Unit in Florence, Italy. IceCure previously announced interim results from this study on October 5, 2023. ProSense is approved in Italy for numerous indications, including breast cancer. In the single-site study conducted between January 2022 and January 2024, ultrasound-guided cryoablation using ProSense was performed on 39 women aged 60-92, who had biopsy-proven malignant lesions, and were deemed inoperable due to advanced age and comorbidities, or who refused surgery. Patients were monitored at 1, 3, 6 and 12 months post-procedure, at which time the tumor size reduction rate was evaluated by ultrasound. The median breast cancer tumor size reduction rates reported in the study were as follows:1 month: 27.8%; 3 months: 60.9%; 6 months: 100.0%; 12 months: 100.0%